Table 1.
Data from patients treated for HCC by TACE. A comparison between the two groups (with and without remission) is included
| Characteristics | Factors | With remission | Without remission | P-value (correlation with CR) | |
|---|---|---|---|---|---|
| Age (years) | Average | 60 (19-80) | 62 (6-87) | 1 (CR is not correlated with age) |
|
| ≥ 55 | 12 (86%) | 120 (81%) | |||
| < 55 | 2 (14%) | 28 (19 %) | |||
| Gender | Males | 11 (78%) | 67 (45%) | 0.023 (CR is correlated with male gender) |
|
| Females | 3 (22%) | 81 (55%) | |||
| PS | PS 0 | 7 (50%) | 73 (50%) | 0.538 (CR is not correlated with PS) |
|
| PS 1 | 6 (43%) | 53 (36%) | |||
| PS 2 | 1 (7%) | 14 (10%) | |||
| PS 3 | 0 | 6 (4%) | |||
| Cause | VHC | 9 (65%) | 69 (48%) | 0.0001 (CR is correlated with VHC) |
|
| VHB | 2 (14%) | 32 (21%) | |||
| PBC | 1 (7%) | 1 (7%) | |||
| Alagille syndrome | 1 (7%) | 1 (7%) | |||
| Wilson syndrome | 0 | 1 (7%) | |||
| Not identified | 1 (7%) | 0 | |||
| AFP (ng/ml) | Average | 3158 (1-22069) | 2884 (50-120560) | 0.35 (CR is not correlated with AFP) |
|
| < 20 | 6 (43%) | 60 (40%) | |||
| < 400 | 9 (64%) | 112 (76%) | |||
| Child-Pugh score | A | 11 (79%) | 83 (61%) | 0.001 (CR is correlated with Child-Pugh score A) |
|
| B | 3 (21%) | 50 (37%) | |||
| C | 0 | 3 (2%) | |||
| MELD score | Average | 10 (8-12) | 5 (1-86) | 0.0001 (CR is correlated with MELD score ≤ 19) |
|
| ≤ 9 | 11 (78%) | 105 (86%) | |||
| 10-19 | 3 (22%) | 9 (7%) | |||
| 20-29 | 0 | 4 (3%) | |||
| 30-39 | 0 | 2 (2%) | |||
| ≥ 40 | 0 | 2 (2%) | |||
| Number of lesions | 1 | 11 (78%) | 100 (61%) | 0.96 (CR is not correlated with number of lesions) |
|
| 2 | 3 (22%) | 52 (31%) | |||
| 3 | 0 | 4 (2%) | |||
| 4 | 0 | 2 (1%) | |||
| 5 | 0 | 5 (3%) | |||
| 6 | 0 | 1 (1%) | |||
| 7 | 0 | 1 (1%) | |||
| Location | Segment I | 0 | 2 | 0.00003 (CR is correlated with segments VI and VII) |
|
| Right lateral sector (RLS) | Total: | 9 (53%) | 32 (15%) | ||
| Segment VI | 3 (18%) | 9 (4%) | |||
| Segment VII | 5 (29%) | 17 (8%) | |||
| Both or between | 1 (6%) | 6 (3%) | |||
| Right paramedian sector (RPMS) | Total: | 3 (18%) | 35 (17%) | ||
| Segment V | 2 (12%) | 12 (6%) | |||
| Segment VIII | 1 (6%) | 21 (10%) | |||
| Both or between | 0 | 2 (1%) | |||
| Location | Left paramedian sector (LPMS) | Segment IV | 1 (6%) | 2 (1%) | |
| Left lateral sector | Total: | 1 (6%) | 14 (7%) | ||
| Segment II | 0 | 3 (14%) | |||
| Segment III | 0 | 9 (4%) | |||
| Both or between | 1 (6%) | 2 (1%) | |||
| Tumor size per nodule (mm) | Average | 81 (17-145) | 56 (12-136) | 0.9 (CR is not correlated with size) |
|
| < 50 | 10 (54%) | 112 (54%) | |||
| 50-100 | 6 (38%) | 75 (36%) | |||
| > 100 | 1 (8%) | 21 (10%) | |||
| Capsule | Present | 2 (15%) | N/A | N/A | |
| Absent | 15 (85%) | N/A | |||
| BCLC stage | A | 1 (7%) | 117 (57%) | 0.0001 (CR is correlated with BCLC stage B and C) |
|
| B | 5 (36%) | 5 (2%) | |||
| C | 8 (57%) | 73 (35%) | |||
| D | 0 | 13 (6%) | |||
| Number of TACE sessions | 1 | 7 (50%) | 89 (60%) | 0.245 (CR is not correlated with number of TACE sessions) |
|
| 2 | 5 (36%) | 37 (25%) | |||
| 3 | 1 (7%) | 12 (14%) | |||
| 4 | 1 (7%) | 0 | |||
| 5 | 0 | 0 | |||
| 6 | 0 | 0 | |||
| Duration of follow-up with a complete response | 396 (197-694) | No CR | |||